JP2004107333A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004107333A5 JP2004107333A5 JP2003301176A JP2003301176A JP2004107333A5 JP 2004107333 A5 JP2004107333 A5 JP 2004107333A5 JP 2003301176 A JP2003301176 A JP 2003301176A JP 2003301176 A JP2003301176 A JP 2003301176A JP 2004107333 A5 JP2004107333 A5 JP 2004107333A5
- Authority
- JP
- Japan
- Prior art keywords
- arg
- cys
- tyr
- cit
- glutamic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 93
- 239000004475 Arginine Substances 0.000 claims 91
- 235000009697 arginine Nutrition 0.000 claims 91
- 229960003121 arginine Drugs 0.000 claims 91
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 91
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 90
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 90
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 79
- 235000013477 citrulline Nutrition 0.000 claims 79
- 229960002173 citrulline Drugs 0.000 claims 79
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 68
- 229960003767 alanine Drugs 0.000 claims 68
- 235000004279 alanine Nutrition 0.000 claims 68
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 66
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 66
- 239000004472 Lysine Substances 0.000 claims 65
- 235000018977 lysine Nutrition 0.000 claims 65
- 229960003646 lysine Drugs 0.000 claims 65
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 52
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 52
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 52
- 229960003104 ornithine Drugs 0.000 claims 52
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 42
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 23
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 23
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 23
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 22
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 22
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 22
- 235000013922 glutamic acid Nutrition 0.000 claims 22
- 229960002989 glutamic acid Drugs 0.000 claims 22
- 239000004220 glutamic acid Substances 0.000 claims 22
- 229960002429 proline Drugs 0.000 claims 22
- 239000004471 Glycine Substances 0.000 claims 21
- 229960002449 glycine Drugs 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 15
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 12
- 229940024606 amino acid Drugs 0.000 claims 11
- 235000001014 amino acid Nutrition 0.000 claims 11
- 150000001413 amino acids Chemical class 0.000 claims 11
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 11
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims 11
- 229960004441 tyrosine Drugs 0.000 claims 11
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 11
- 235000002374 tyrosine Nutrition 0.000 claims 11
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 11
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 claims 10
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 10
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 10
- 229960005190 phenylalanine Drugs 0.000 claims 10
- -1 glutaryl Chemical group 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 125000004077 D-glutamic acid group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(N([H])[H])=O 0.000 claims 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine group Chemical group N[C@H](CCCCN)C(=O)O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 2
- 230000003449 preventive effect Effects 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims 2
- 229960003732 tyramine Drugs 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- RHGKLRLOHDJJDR-SCSAIBSYSA-N D-citrulline Chemical group OC(=O)[C@H](N)CCCNC(N)=O RHGKLRLOHDJJDR-SCSAIBSYSA-N 0.000 claims 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 1
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 claims 1
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 claims 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 claims 1
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 claims 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical group C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 claims 1
- 0 CC(CCCCN=C(*)N(C)C)=O Chemical compound CC(CCCCN=C(*)N(C)C)=O 0.000 description 5
- ASTWRTDZVPHBPJ-XJOVWXOCSA-N CC(CCC(O[C@H](CN(C[C@@H](CCCC1)[C@@H]1C1)[C@@H]1C(N)O)C(CSc1ccccc1)NC(c1cccc(O)c1C)=O)=O)=O Chemical compound CC(CCC(O[C@H](CN(C[C@@H](CCCC1)[C@@H]1C1)[C@@H]1C(N)O)C(CSc1ccccc1)NC(c1cccc(O)c1C)=O)=O)=O ASTWRTDZVPHBPJ-XJOVWXOCSA-N 0.000 description 1
- UXBBHWRHCMRUMV-ZCFIWIBFSA-N CC[C@H](CCCNC(N)=N)N Chemical compound CC[C@H](CCCNC(N)=N)N UXBBHWRHCMRUMV-ZCFIWIBFSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003301176A JP4781621B2 (ja) | 2002-08-27 | 2003-08-26 | Cxcr4拮抗薬およびその用途 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002247843 | 2002-08-27 | ||
| JP2002247843 | 2002-08-27 | ||
| JP2003301176A JP4781621B2 (ja) | 2002-08-27 | 2003-08-26 | Cxcr4拮抗薬およびその用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011060367A Division JP5315372B2 (ja) | 2002-08-27 | 2011-03-18 | Cxcr4拮抗薬およびその用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004107333A JP2004107333A (ja) | 2004-04-08 |
| JP2004107333A5 true JP2004107333A5 (cg-RX-API-DMAC7.html) | 2006-09-14 |
| JP4781621B2 JP4781621B2 (ja) | 2011-09-28 |
Family
ID=32301222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003301176A Expired - Fee Related JP4781621B2 (ja) | 2002-08-27 | 2003-08-26 | Cxcr4拮抗薬およびその用途 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4781621B2 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105163749B (zh) * | 2013-03-24 | 2018-03-27 | 拜欧肯治疗有限公司 | 治疗骨髓性白血病的方法 |
| MX2017016844A (es) | 2015-07-16 | 2018-08-15 | Biokine Therapeutics Ltd | Composiciones y procedimientos para tratar cancer. |
| CA3014530A1 (en) | 2016-02-23 | 2017-08-31 | Biolinerx Ltd. | Methods of treating acute myeloid leukemia |
| BR112021008797A2 (pt) * | 2018-11-09 | 2021-08-31 | Neopep Pharma Gmbh & Co. Kg | Polipeptídeos para o tratamento de síndromes de estresse, imunorreação e derrame |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69416824T2 (de) * | 1993-10-14 | 1999-07-08 | Seikagaku Corp., Tokio/Tokyo | Polypeptide und daraus hergestellte, gegen hiv wirksame substanzen |
| DE69914463T2 (de) * | 1998-03-13 | 2004-11-11 | The University Of British Columbia, Vancouver | Therapeutische chemokine rezeptor antagonisten |
| CA2389979C (en) * | 1999-11-24 | 2011-08-16 | Schering Corporation | Methods of inhibiting metastasis |
| DE60103052T2 (de) * | 2000-05-09 | 2005-03-03 | The University Of British Columbia, Vancouver | Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten |
| EP1323730B1 (en) * | 2000-09-05 | 2010-04-21 | Biokine Therapeutics Ltd. | Novel polypeptides and anti-hiv drugs containing the same |
-
2003
- 2003-08-26 JP JP2003301176A patent/JP4781621B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013500990A5 (cg-RX-API-DMAC7.html) | ||
| CA3188410A1 (en) | Conjugated hepcidin mimetics | |
| RU2004110726A (ru) | Применение оксинтомодулина, способ и фармацевтическая композиция для профилактики или лечения избыточной массы тела, способ снижения массы тела | |
| JP2010529957A5 (cg-RX-API-DMAC7.html) | ||
| JP2020502183A5 (cg-RX-API-DMAC7.html) | ||
| CO5590884A2 (es) | Molecula de insulina que tiene una accion en el tiempo prolongada | |
| CA2370289A1 (en) | Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides | |
| JP2008525430A5 (cg-RX-API-DMAC7.html) | ||
| JP2011511753A5 (cg-RX-API-DMAC7.html) | ||
| JP2004521123A5 (cg-RX-API-DMAC7.html) | ||
| NZ613252A (en) | Peptide epoxyketones for proteasome inhibition | |
| HRP20041108B1 (hr) | Peptidi povezani sa tumorom koji se vežu na mhc molekule | |
| EP1614675A3 (en) | Amino acids with affinity for the alpha-2-delta protein | |
| JP2006506942A5 (cg-RX-API-DMAC7.html) | ||
| WO2007027640A3 (en) | Stabilized virus-like particles and epitope display systems | |
| EA200501131A1 (ru) | Парентеральные композиции пептидов для лечения системной красной волчанки | |
| EP1323730A4 (en) | NEW POLYPEPTIDES AND ANTI-HIV DRUGS CONTAINING THEM | |
| WO2007145589A8 (en) | Peptides that are capable of binding to amyloid-beta peptide. | |
| CY1112839T1 (el) | Πεπτιδια χ-κωνοτοξινες που εχουν ενα αμινοτελικο πυρογλουταμικο οξυ | |
| RU2010128602A (ru) | Циклический белок, не содержащий остатков цистеина | |
| ES2377808T3 (es) | Péptidos antibacterianos | |
| RU2011133224A (ru) | Новые фармацевтические композиции | |
| RU2009103811A (ru) | Аналоги вазоактивного интестинального пептида | |
| JP2021506815A5 (cg-RX-API-DMAC7.html) | ||
| JP2006505555A5 (cg-RX-API-DMAC7.html) |